{
  "claim_id": "claim_000",
  "claim": "Flublok ensures identical antigenic match with WHO- and FDA-selected flu strains.",
  "document": "Zimmerman_et_al.__2023_",
  "verification_stats": {
    "total_extracted": 2,
    "verified": 0,
    "rejected": 2,
    "verification_rate": 0.0
  },
  "verified_evidence": [],
  "rejected_evidence": [
    {
      "id": 1,
      "quote": "RIV4 was Flublok",
      "reason": "does not support claim",
      "original_explanation": "This identifies Flublok as the recombinant influenza vaccine (RIV4) being studied, which is relevant because the claim is about Flublok's antigenic match."
    },
    {
      "id": 2,
      "quote": "because it is not subject to mutations to the A (H3 N2) glycosylation binding site that reduce the effectiveness of egg based vaccines.",
      "reason": "does not support claim",
      "original_explanation": "This statement supports the claim by indicating that Flublok (RIV4) is not subject to egg-adapted mutations, which can cause antigenic mismatch in egg-based vaccines, thus implying that Flublok maintains an identical antigenic match to the selected strains."
    }
  ],
  "model_used": "gpt-4.1"
}